- Terutroban
Drugbox
IUPAC_name = Sodium 3- [6(R)-(4-chlorophenylsulfonamido)-2-methyl-5,6,7,8-tetrahydronaphth-1-yl] propionate
CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem =
DrugBank =
chemical_formula =
C=20 | H=21 | Cl=1 | N=1 | Na=1 | O=4 | S=1
molecular_weight = 429.892 g/mol
smiles = O=C( [O-] )CCc1c2CCC(Cc2ccc1C)NS(=O)(=O)c3ccc(Cl)cc3. [Na+]
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 6-10 hours
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Investigational
routes_of_administration = OralTerutroban is an
antiplatelet agent developed byServier Laboratories . as of|2008, it is tested for the secondary prevention of acute thrombotic complications in thePhase III clinical trial PERFORM.Method of action
Terutroban is a selective antagonist of the
thromboxane receptor . It blocks thromboxane inducedplatelet aggregation andvasoconstriction .References
* cite journal
author = H. Spreitzer
date =January 29 ,2007
title = Neue Wirkstoffe - Terutroban
journal = Österreichische Apothekerzeitung
issue = 3/2007
pages = 116
language = German
* cite journal
author = Sorbera, LA, Serradell, N, Bolos, J, Bayes, M
title = Terutroban sodium
journal = Drugs of the Future
year = 2006
volume = 31
issue = 10
pages = 867-873
Wikimedia Foundation. 2010.